Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease. by Anandappa, S. Y. et al.
Br. J. Cancer (1994), 69, 772-776 © Macmillan Press Ltd., 1994~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Comparative expression of fibroblast growth factor mRNAs in benign and
malignant breast disease
S.Y. Anandappa', J.H.R. Winstanley2, S. Leinster2, B. Green3, P.S. Rudland' & R. Barraclough'
Departments of 'Biochemistry, 2Surgery and 3Pathology, University ofLiverpool, PO Box 147, Liverpool, 69 3BX, UK.
Summary The messenger RNAs for the angiogenic acidic and basic fibroblast growth factors are expressed at
a significantly higher level in samples of human benign neoplastic and hyperplastic tissue than in samples from
breast cancers. However, approximately one in four malignant breast cancer samples contain basic fibroblast
growth factor mRNA at the same level as in the benign lesions when basic fibroblast growth factor mRNA
levels are corrected with respect to levels of expression of glyceraldehyde-3-phosphate dehydrogenase mRNA.
A similar proportion of human malignant breast cancer cell lines express a high level of basic fibroblast
growth factor mRNA. The results suggest that some malignant breast cancers and their constitutive carcinoma
cells express abundant levels of basic fibroblast growth factor mRNA. The resultant production of basic
fibroblast growth factor by breast cancer cells within some tumours may contribute to their development.
It is now recognised that abnormal expression of growth
factors and their receptors is a relatively common feature of
a number ofcancers. This is particularly true ofcarcinoma of
the breast, in which abnormal expression of, for example, a
growth factor receptor has been identified as an important
new means of assessing prognosis (Slamon et al., 1987; Win-
stanley et al., 1991). Amplification of genes for certain
growth factors has also been observed in breast cancers, in
particular two members of the fibroblast growth factor
(FGF) family, the oncogenes int-2 and hst-I (Lidereau et al.,
1988; Theillet et al., 1989). Two other members of this
family, acidic FGF and basic FGF, are found in cell lines
derived from the normal or benign rodent (Barraclough et
al., 1990) and human (Ke et al., 1993) mammary tissue. Both
these growth factors are angiogenic (Folkman & Shing,
1992), and basic FGF is thought to be trophic for the rodent
mammary gland (Barraclough et al., 1990). Since it has been
shown that angiogenesis is important in the growth of breast
cancers and may affect their clinical outcome (Weidner et al.,
1991), abnormal expression of these growth factors may be
of potential importance in understanding the biology of
breast cancer.
Materials and methods
Tumour specimens
Tumour specimens were obtained from patients with primary
operable breast cancer treated by the Department of Surgery,
University of Liverpool, between 1988 and 1992. Samples
(about 300 mg) of breast lumps were snap frozen in liquid
nitrogen at the time of surgery and stored in liquid nitrogen
until required for the isolation of RNA. Adjacent samples of
the tumour were taken and fixed in Methacarn for embed-
ding in paraffin. Subsequently, 5 ym histological sections
were cut and used to check that the specimen was represen-
tative of the histological diagnosis. Lymph node status was
based on the results of either axillary clearance or axillary
sampling at the time of surgery. The benign lesions consisted
of fibroadenoma (five samples), atypical hyperplasia (two
samples), fibrocystic disease (nine samples) and sclerosing
adenosis and duct ectasia (three samples). In addition, three
samples were found to consist of normal tissue. Inclusion of
the samples of normal breast in the benign lesion group did
not alter the statistical significance of the results. The car-
cinomas consisted ofprimary tumours of the following types:
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invasive ductal (86 samples), invasive lobular (seven samples),
invasive cribriform (one sample), medullary (one sample) and
mucinous (two samples). Five carcinomas in situ (four ductal
and one lobular) were also included in this category for the
purpose of statistical analysis, however their omission did not
alter the statistical significance of the results. All histological
grades and stages were observed, but they were not treated
separately in this analysis. The mean age of patients with
malignant tumours was 57 (range 30-88) and the mean age
of those patients with benign lesions was 44 (range 19-65).
Cell culture
Five established human breast carcinoma cell lines, MCF-7,
MDA-MB-231, SK-Br-3, T-47D and ZR-75, were derived
from the pleural effusion of breast cancer patients (Engel &
Young, 1978). Cell line MCF-7 was grown in Dulbecco's
modified Eagle medium (DMEM) containing 5% fetal calf
serum, 1 ggml1' insulin, 1 ngml-' epidermal growth factor
and 50 ngml-' hydrocortisone; cell lines MDA-MB-231 and
T-47D were grown in DMEM containing 10% fetal calf
serum, 1 figml-' insulin, 2.5 ngml-' epidermal growth factor
and 50 ngml-' hydrocortisone; cell line SK-Br-3 was grown
in DMEM containing 20% fetal calf serum, 50 ngml-'
insulin and 50 ngml-' hydrocortisone; and cell line ZR-75
was grown in DMEM containing 5% fetal calf serum,
50 ngml-' insulin, 2.5 ngml1 epidermal growth factor, 50
ngml1 hydrocortisone and 10-8M oestradiol. All cells were
passaged when they reached 70-80% confluence.
Isolation ofRNA
Poly(A)-containing RNA was isolated from cultured cell lines
either according to previously described methods using guan-
idinium isothiocyanate (Aviv & Leder, 1972; Chirgwin et al.,
1979; Barraclough et al., 1987; Han et al., 1987) or using a
Fast-Track mRNA isolation kit (Invitrogen Corporation).
Total RNA was isolated from the tissue samples using
methods designed to reduce the activity of ribonucleases.
Tissue samples were converted to a powder while still frozen
using a brass pestle and mortar at - 70'C, and the resulting
frozen and powdered tissue was rapidly transferred into
either 16 or 8 ml of a guanidinium isothiocyanate buffer
system (Chirgwin et al., 1979) containing an elevated concen-
tration of 2-mercaptoethanol (Han et al., 1987) to reduce
ribonuclease activity. The tissue powder was solubilised im-
mediately by homogenisation in a Polytron at 16,000 r.p.m.
The homogenate was centrifuged at 7,700g(av) for 10 min
(Chirgwin et al., 1979) to sediment any remaining unsolu-
bilised tissue, and the supernatant was layered over a cushion
of 5.7 M caesium chloride and centrifuged for at least 18 h at
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120,000g(av,) in an ultracentrifuge to sediment the RNA
(Chirgwin et al., 1979; Barraclough et al., 1987). The pellet of
RNA was dissolved in 0.1% (w/v) SDS solution and the
RNA precipitated with ethanol; 99% of such samples yielded
RNA. RNA samples were quantified by measuring their
optical density at 260 nm and their quality was determined
by their pattern of Northern hybridisation (Sambrook et al.,
1989).
Nucleic acidprobes
Synthetic genes corresponding to the coding regions of
human acidic FGF and basic FGF mRNAs (British Biotech-
nology, Oxford, UK; Barraclough et al., 1990) and a cDNA
corresponding to human glyceraldehyde-3-phosphate dehyd-
rogenase (GAPD, American Type Culture Collection No.
57091) were radioactively labelled with [32P]dCTP by the
method of random-primed synthesis (Feinberg & Vogelstein,
1984) to specific activities of 1-3 x 109d.p.m. per gxg of
DNA.
Northern blotting andhybridisation
Poly(A)-containing RNA (10fig) isolated from human malig-
nant cell lines, or total RNA (10fig) isolated from tissue
samples, was subjected to agarose gel electrophoresis in the
presence of the denaturing agent, formaldehyde. The gels
were then washed to remove the denaturing agent (Alwine et
al., 1977) and the RNA was transferred onto nylon filters
(Hybond, Amersham International, UK) using standard No-
rthern blotting procedures (Sambrook et al., 1989).
The filters were incubated with prehybridisation buffer
consisting of 50% (v/v) deionised formamide, 5 x SSPE
(1 x SSPE contains 0.15 M sodium chloride, 10 mM sodium
dihydrogen phosphate, 1 mM EDTA), 5 x Denhardt's solu-
tion [1 x Denhardt's solution contains 0.02% (w/v) bovine
serum albumin, 0.02% (w/v) polyvinylpyrrolidone, 0.02%
(w/v) Ficoll], 0.5% (w/v) SDS and 50tgml-l denatured,
sonicated salmon sperm DNA for 5 h at 42°C in a rotisserie-
action hybridisation oven. The filters were then incubated
with 5 ml of prehybridisation buffer containing 10% (w/v)
dextran sulphate and 25 ng of 32P-labelled cDNA (either the
acidic FGF or the basic FGF and GAPD) at 42°C for at
least 16 h. Filters were washed in a buffer consisting of
1 x SSPE/0.1% SDS, once for 30 min at room temperature,
and then for 2 h at 65°C. Radioactivity bound to the filters
was detected by autoradiography at - 70°C using Kodak
X-AR film and an intensifying screen for 8 or 14 days (acidic
FGF), 4-13 days (basic FGF) or against Fuji RX X-ray
film at room temperature for either 16 h or 4 days (GAPD).
Using the hybridisation conditions described above, the aci-
dic FGF probe did not hybridise to the mRNA for basic
FGF, and the basic FGF probe failed to hybridise to the
mRNA for acidic FGF. Since there was no cross-hybridi-
sation between the mRNAs of these closely related members
of the FGF family of proteins, it is unlikely that either probe
would hybridise to the mRNAs of other, more distantly
related members of the FGF family. The autoradiographic
images arising from hybridisation of the acidic FGF, basic
FGF or GAPD probes to the RNA samples of the tissues
were scanned using a Shimadzu C9000 flying spot densi-
tometer using a beam size of 0.4 x 5 mm at a wavelength of
600 nm. For the acidic FGF mRNA at the 4 kb region and
for the basic FGF mRNA, the 7 kb region of the autoradio-
graph was scanned. However, for the GAPD, the entire lane
below an apparent molecular size of 2 kb was scanned.
Values of peak areas were obtained by integration.
The peak area data for each sample, representing the level
of hybridisation to the mRNAs for acidic or basic FGF
probes, were expressed as a ratio between the peak area of
the band of hybridisation of the FGF probe and the peak
area of the band arising from the hybridisation of the same
sample to the glyceraldehyde-3-phosphate dehydrogenase
probe. To eliminate possible variations in the loading of
RNA from well to well of a single agarose gel and variations
in the degree of cellularity of the sample from which the
RNA had been isolated, these ratios were normalised to the
level of glyceraldehyde-3-phosphate dehydrogenase mRNA in
one particular RNA sample. Owing to the large number of
samples analysed, it was necessary to compare the results of
many blotting and hybridisation experiments, and the signal
strength of these different experiments will be affected by
variables such as the efficiency of transfer of the RNA from
gel to nylon filter, the precise specific activity of radioactive
probe, the efficiency of hybridisation and the autoradio-
graphic exposure time. To correct for these variables, a con-
trol RNA sample was subjected to electrophoresis, blotting
and hybridisation in every experiment. Providing there was
no variation in loading in these control samples, and this was
ensured, the level of the basic FGF mRNA in these samples
on different gels provides a measure of variabilities in the
hybridisation procedures. The corrected FGF/GAPD result
for each sample on a gel was therefore additionally nor-
malised to a constant level of FGF mRNA expression of the
control RNA sample.
Results
mRNAfor basic FGFand GAPD in human cell lines
Samples of poly(A)-containing RNA from five malignant
human mammary cell lines were hybridised with cDNA pro-
bes to GAPD and basic FGF mRNA. The GAPD DNA
hybridised to a band of 1.5 kb in RNA from all five cell
lines, indicating that the mRNAs were not degraded (Figure
1). The RNA from the MDA-MB-231 cells contained basic
FGF mRNA molecules of 7.2, 4.1, 2.2 and 1.1 kb in size
(Figure 1), whereas it was not possible to detect any mRNA
for basic FGF in the remaining four malignant cell lines,
SK-Br-3, ZR-75, MCF-7 and T-47D (Figure 1), even at
higher loadings of RNA (Figure 1).
mRNAfor basic FGF, acidic FGFand GAPD in human
tumour samples
RNA isolated from the tumour samples contained molecules
that hybridised to the GAPD probe. The DNA probe for
GAPD hybridised to a band of RNA of 1.50 ± 0.05 kb
(mean ± s.d. of 12 determinations). The level ofhybridisation
in different samples was variable, reflecting the expected
different cellularity of the tumours (Figures 2 and 3). The
cDNA probe corresponding to acidic FGF mRNA detected a
single band of RNA at 4.1 ± 0.3 kb (mean ± s.d. of 12 deter-
minations) (Figure 2). The DNA probe corresponding to
basic FGF mRNA showed one of three, more complex pat-
terns of hybridisation. The first pattern (exemplified by lane
7, Figure 3), was of almost undetectable hybridisation by the
basic FGF cDNA to RNA samples in which the GAPD
probe hybridised to intact mRNA. In these samples, the lack
ofhybridisation by the basic FGF probe was due to the level
of basic FGF mRNA being close to the level of detection at
the exposure times used. In the second pattern of hybridisa-
tion (exemplified by lanes 8-11, Figure 3), the basic FGF
cDNA hybridised to mRNA molecules ofapparent molecular
sizes 7.2 ± 0.2 kb (mean ± s.d of 12 determinations) and
4.3 ± 0.2 kb (mean ± s.d. of 12 determinations). These bands
correspond to the bands of hybridisation of 7.2 and 4.1 kb
observed in the cell lines ofmalignant tumour (Figure 1) and
benign tissue origins (Ke et al., 1993). The remaining two
bands of 2.2 and 1.1 kb seen in the cell lines (Figure 1; Ke et
al., 1993) were not always clearly resolved in the tumour
samples. The third type of hybridisation pattern, due to
degradation of the 7.2kb mRNA (Figure 3, lane 4), was
distinguishable from the undegraded pattern (Figure 3, for
example lanes 8-11). Any tumours showing evidence of deg-
radation of the 7.2 kb basic FGF mRNA were omitted from
the subsequent analysis of the results.
For hybridisation to the acidic FGF probe, 94 tissue sam-
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logically malignant, 17 were diagnosed as histologically
benign and two contained only apparently normal tissue. For
hybridisation to the basic FGF probe, a total of 124 tissue
samples were examined: 102 were classified as histologically
malignant, 19 were classified as histologically benign and
three contained only apparently normal tissue. There was no
quantitative relationship between the level of expression of
mRNAs for acidic FGF and for basic FGF (not shown).
mRNAs for acidic FGF and basic FGF were undetectable in
10 (11%) and 33 (27%) of the tumours respectively; all of
these samples were malignant tumours. In contrast, the
benign lesions were among those that expressed the highest
levels of acidic FGF or basic FGF mRNA (Table I) when
the levels of fibroblast growth factor mRNA in all samples
were corrected with respect to the levels of glyceraldehyde-3-
phosphate dehydrogenase mRNA expression. The results are
shown graphically in Figure 4. The mean level of expression
of the mRNA for either acidic or basic FGF in malignant
cancers was statistically significantly lower than in the his-
tologically benign lesions (Mann-Whitney U-test, Table I).
For the results of the level of expression of basic FGF
mRNA, approximate 95% confidence intervals were con-
structed for the medians of the benign tissue (median 39,915;
confidence interval 19,013-65,752) and malignant tumours
(median 4,267; confidence interval 2,492-6,633). The wide
confidence intervals reflect the large range in the values for
the basic FGF mRNA, but their lack of overlap confirms the
results of the hypothesis test.
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Discussion
None of the 124 tumour samples tested showed any evidence
of the production of abnormal forms of the mRNAs for
either basic or acidic FGF when compared with existing
1 2 3 4 5 6 7 8 9 10 11 12
4kb-
1.5 kb-
Figure 2 Expression of acidic FGF mRNAs from samples of
normal breast tissue and breast lesions. The result of a typical
Northern blot is shown. Each lane represents a single tissue
sample. Samples 1,3,4,5,6,7,8,9 and 12 are from carcinomas, sam-
ples 2 and 10 are from benign lesions, sample 11 is from normal
breast tissue and samples 3 and 4 show some evidence of deg-
radation of the RNA. a, The location of the 4 kb acidic FGF
mRNA is indicated by the band of radioactivity visualised by
exposure to Kodak XAR-5 X-ray film for 14 days at - 70C with
an intensifying screen. b, The location of the constitutively ex-
pressed 1.5 kb GAPD mRNA is indicated by the band of radio-
activity visualised by exposure to Fuji RX X-ray film overnight at
room temperature.
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Figure 1 Expression of mRNA for basic FGF in human breast
carcinoma cell lines. Poly(A)-containing RNA isolated from
human breast carcinoma cell lines was subjected to formalde-
hyde-agarose gel electrophoresis and blotted onto nylon filters.
The filters were incubated with probes corresponding to human
basic FGF mRNA or human glyceraldehyde-3-phosphate dehydro-
genase (GAPD). a, Detection of the mRNA for basic FGF in the
breast carcinoma cell line, MDA-MB-231. The upper panel shows
the four mRNAs for basic FGF. The lower panel shows the
intensity of the constitutively expressed GAPD mRNA. The
numbers on the left indicate the molecular sizes in kb. b, The
upper panel shows the relative levels of the mRNA for basic
FGF in human breast cancer cell lines SK-Br-3 (lane 1), ZR-75
(lane 2), MCF-7 (lane 3), T-47D (lane 4) and two independent
preparations of RNA from cell line MDA-MB-231 (lanes 5 and
6). Bands of basic FGF radioactivity were visualised by exposure
to Kodak XAR-5 X-ray film for 12 days at - 70°C with an
intensifying screen. The loading of the RNA from the negative
cell lines is higher than that of the positive MDA-MB-231 cell
line. The lower panel shows the intensity of the constitutively
expressed GAPD mRNA.
1.5kb --
Figure 3 Expression of basic FGF mRNAs from samples of
normal breast tissue and breast lesions. The result of a typical
Northern blot is shown. Each lane represents a single tissue
sample. Samples 1,3,4,5,6,7,8,9 and 12 are from carcinomas, sam-
ples 2 and 10 are from benign lesions, sample 11 is from normal
breast tissue. Samples 3 and 4 show some evidence of degrada-
tion of the RNA. a, The location of the 7.2 kb basic FGF
mRNA is indicated by the band of radioactivity visualised by
exposure to Kodak XAR-5 X-ray film for 13 days at - 70'C with
an intensifying screen. b, The location of the constitutively ex-
pressed 1.5 kb GAPD mRNA is indicated by the band of radio-
activity visualised by exposure to Fuji RX X-ray film overnight at
room temperature.BASIC FGF mRNA IN BREAST TUMOURS 775
Table I Levels of mRNA for acidic and basic FGF in benign breast
tissue and malignant tumours
Number (%) of
Corrected level of histologically Number (%) of
FGF mRNA benign lesions or histologically
(arbitrary units)a normaltissuesamples malignant tumours
Acidic FGF
<1 X 103 0 (0) 12 (16)
1-15 x 103 2 (10.5)b 52 (69)
15-30 x 103 2 (10.5)c 10 (14)
>30 x 103 15 (79)C 1 (1)
Mean level ± s.d. 53,794 + 27,298 7,127 ± 10,730d
Basic FGF
< I X 103 0 (0) 33 (32)e
X 103 to 1.1x 104 0 (0) 41 (40)
1.2 x 104 to 1 x 105 20 (9I)f 24 (24)8
1 x 10 to xIO106 2 (9)c 4 (4)h
Mean level ± s.d. 47,723 + 32,035 16,755 ± 36,591d
aIn order to compare the results of samples run on different
agarose gels, which were blotted and hybridised on separate
occasions, the results of the hybridisations to the acidic or basic
FGF mRNA were not only corrected for variations in sample
loading, by being corrected for the level of GAPD in that sample,
but were also corrected for variations resulting from the specific
radioactivity of the DNA probe used, the efficiency of hybridisation
and the length oftime ofautoradiographic exposure. The application
of these corrections is described in the Materials and methods
section. bSamples were normal mammary tissue. cSamples were
benign lesions. 'Significantly lower than benign/normal tissue
(P<0.0001; Mann-Whitney U-test); significantly lower than benign
tissue (P<0.0001; Mann-Whitney U-test). 'Includes one lobular
carcinoma in situ and one ductal carcinoma in situ.fSamples were 17
benign lesions and three normal tissue. glncludes two ductal
carcinomas in situ. hIncludes one ductal carcinoma in situ.
benign (Ke et al., 1993) or malignant (Figure 1) breast cell
lines. There was, however, a highly statistically significant
difference between benign and malignant lesions in the mean
level of expression of the mRNAs for either acidic FGF or
basic FGF. Since cultured epithelial and myoepithelial-like
cells derived from benign lesions fail to express detectable
levels of acidic FGF mRNA (Barraclough et al., 1990; Ke et
al., 1993), it is likely that much of this mRNA is derived
from the stromal elements within the tissue samples. How-
ever, there was no consistent relationship between the levels
of expression of the mRNAs for acidic FGF and basic FGF
in each tumour, suggesting that these two mRNAs are
independently expressed in the breast tumour samples.
Basic FGF and its mRNA are synthesised by rat (Barra-
clough et al., 1990) and human (Ke et al., 1993) myoepi-
thelial-like cells in culture, but not by the epithelial cells
within the mammary gland in vivo. Immunocytochemical
studies have shown that basic FGF is localised primarily to
the basement membrane and to a lesser extent to the myo-
epithelial cells in the normal rat and human breast and in
benign breast tissue (Gomm et al., 1991; Rudland et al.,
1993a); its cellular location in growing rat ductal structures is
consistent with its synthesis by the myoepithelial-like but not
the epithelial cells (Rudland et al., 1993a). Myoepithelial cells
are found in both normal and benign breast tissue, but are
lost in human invasive breast carcinromas (Gusterson et al.,
1982; Rudland et al., 1993b). The observation that invasive
carcinomas generally express lower levels of basic FGF
mRNA than does benign/normal tissue (this paper) and a
similar previous report (Luqmani et al., 1992) are possibly
consistent with the loss of myoepithelial cells in the invasive
carcinomas. Although in the present work there was no
overall increase in the expression of the mRNA for basic
FGF in the malignant breast tumours relative to that in the
benign tissue, approximately 25% of the malignant tumours
(excluding the 'in situ' carcinomas, Table I) did express basic
FGF mRNA at levels that were equivalent to, or higher
than, those of the benign tissue. A similar proportion (20%) of
the malignant human mammary cell lines tested expressed
Figure 4 A whisker plot showing the median (0) and quartile
values (bars) for the levels of mRNAs for acidic FGF (aFGF)
and basic FGF (bFGF) in samples of benign breast tissues (B)
and of malignant carcinomas (M). For acidic FGF mRNA, the
median, upper and lower quartile values were, respectively, 4,059,
9,245 and 1,707 for malignant tumours and 55,767, 79,002 and
41,410 for benign tissue. For basic FGF mRNA the median,
upper and lower quartile values were, respectively, 4,267, 13,413
and zero for malignant tumours, and 39,915, 65,752 and 19,013
for benign tissue.
high level of basic FGF mRNA (Figure 1), and a similar
proportion of cell lines expressing basic FGF mRNA has
been previously reported (Li & Shipley, 1991; Luqmani et al.,
1992), although Luqmani et al. (1992) detected the mRNA
for basic FGF in the cell line ZR-75-1 using an assay based
on the polymerase chain reaction. All of these results toge-
ther strongly suggest that, in some breast cancers, there is a
population of tumour cells that acquire the ability to express
high levels of basic FGF mRNA. Indeed, we have observed
immunocytochemically detectable basic FGF in the malig-
nant cells of some invasive human breast carcinomas using
four independently isolated antibodies to basic FGF (Rud-
land et al., 1993b), but the precise quantitation is dependent
on the antibody used (unpublished results). Since basic FGF
is angiogenic and angiogenesis is an important feature of
tumour growth and metastasis (Weidner et al., 1991), the
ability of subclones of malignant epithelial cells to express
basic FGF might favour the establishment of a more success-
fully metastasising breast cancer. However, since most of the
released basic FGF is probably sequestered by nearby glycos-
aminoglycans in vitro (Fernig et al., 1992) and in vivo (Rud-
land et al., 1993a), the role of basic FGF in breast cancer is
by no means clear cut.
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